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ABSTRACT  
In the brain, serotonin (5-hydroxtryptamine, 5-HT) is synthesized in the raphe nucleus. 
Raphe serotonergic projections modulate neurotransmissions throughout the brain 
influencing mood and behavior. The serotonin transporter (SERT; SLC6A4) clears 5-HT 
from the synapse for degradation or reuse, thus regulating levels of 5-HT and limiting its 
actions on 5-HT receptors. Dysfunction in 5-HT modulation of neurotransmission is 
associated with mood and developmental disorders including anxiety, depression, and 
autism and there is genetic evidence for increased risk for depression in individuals 
possessing polymorphisms in SLC6A4 as well as genes which interact with SLC6A4. 
ITGB3 encodes integrin β3, a cell adhesion molecule which has been implicated as a 
modulator of serotonergic systems via genetic and functional interactions with SLC6A4, 
as well as in regulation of synaptic plasticity and maturation. In the brain, integrin β3 
couples to integrin αv to form a functional receptor, making integrin αvβ3 an interesting 
target for regulation of neural 5-HT systems. Immunohistochemical experiments 
revealed integrin β3 localization in serotonergic neurons, colocalized with SERT. 
Examination of genetic interactions utilizing an Itgb3-/+ x Slc6a4-/+ mouse model 
revealed reduced SERT expression, and an anxiety- and depression-like phenotype 
compared to wildtype littermates. Further experimentation of the functional interaction 
between integrin αvβ3 and SERT via pharmacological targeting of integrin αvβ3 
revealed integrin αvβ3 regulation of SERT uptake activity. These studies highlight 
integrin β3 as a potential modulator of brain 5-HT systems and subsequently 5-HT 
mediated behavioral phenotypes. 
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CHAPTER I 
 
INTRODUCTION 
 
The serotonin (5-hydroxytryptamine, 5-HT) signaling pathway modulates neurons 
and their function, and dysregulation of the 5-HT system has been implicated in anxiety, 
depression, and autism (Akimova et al, 2009; Arango et al, 2001; Cook et al, 1990; Fink 
and Gothert, 2007; Gadow et al, 2013; Hoehn-Saric et al, 2000; Leventhal et al, 1990). 
5-HT is cleared from the extracellular milieu by the Na+/Cl- dependent 5-HT transporter 
(SERT) encoded by the SLC6A4 gene (Blakely et al, 1991; Ramamoorthy et al, 1993). 
SERT is the principal target of selective 5-HT reuptake inhibitors (SSRIs), a class of 
therapeutics used extensively in the treatment of anxiety, depression, and autism 
(Anderson, 2004; Serretti and Artioli, 2004). It is probable that SSRIs work by 
preventing reuptake of 5-HT thereby prolonging its actions on 5-HT receptors. A 
diagram of the synaptic serotonergic system is depicted in Figure 1. 
In addition to its documented involvement in the treatment of psychiatric 
conditions, polymorphisms in SLC6A4 have been associated with the etiology of 
anxiety, depression and autism (Caspi et al, 2003; Cook et al, 1990; Kaufman, 2005; 
Lesch et al, 1996; Monti, 2011; Roiser et al, 2006). Many of these studies focus on 
persons who have experienced stressful life events and report a gene x environment 
interaction. Also implicated in 5-HT related mental illnesses are genes which may 
interact with SLC6A4 such as ITGB3 (Weiss et al, 2005) which encodes the integrin β3 
subunit.  
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Figure 1. Model of 5-HT synaptic actions (aan het Rot et al, 2009). 5-HT is synthesized in the 
presynaptic neuron where it is packaged into vesicles for release from the presynaptic 
terminal. Once released into the synaptic cleft 5-HT can act upon postsynaptic 5-HT 
receptors (or presynaptic 5-HT autoreceptors), which then initiate intracellular signaling 
cascades. The actions of 5-HT receptors allow 5-HT to regulate feeding behavior, sleep, 
locomotor activity, learning and memory, and mood (Arango et al, 2001; Monti, 2011; Murphy 
et al, 1999). SERT is located perisynaptically where it can transport extracellular 5-HT back 
into the presynaptic neuron for degradation or reuse, thus limiting 5-HT actions. 
 
 
 
 
3 
 
Integrins are heterodimeric, bidirectional allosteric signaling receptors formed of 
an  and  subunit (Hynes, 2002b). The integrin 3 subunit is expressed in both 
platelets and in neurons. In the brain, integrin 3 is enriched at glutamatergic and 
glycinergic synapses where it has been ascribed various roles including the 
developmental regulation of glutamatergic synapses (Chavis and Westbrook, 2001), 
synaptic strength (Cingolani et al, 2008; Pozo et al, 2012) and glycine receptor 
localization (Charrier et al, 2010). Recent genetic analyses have provided evidence that 
ITGB3 may be involved in serotonergic function (Carneiro et al, 2008; Coutinho et al, 
2007; Cross et al, 2008; Napolioni et al, 2011; Weiss et al, 2005; Weiss et al, 2006a; 
Weiss et al, 2006b). Expression levels of ITGB3 and SLC6A4 are correlated in both 
mice and humans (Weiss et al, 2006b) and several independent studies have revealed 
ITGB3 as a quantitative trait locus for whole blood 5-HT levels (Coutinho et al, 2007; 
Napolioni et al, 2011; Weiss et al, 2005; Weiss et al, 2006a). Carneiro, et al previously 
reported that integrin αIIβ3 directly interacts with SERT and activation of integrin αIIβ3 
results in enhanced SERT uptake activity and elevated SERT plasma membrane 
expression in platelets (Carneiro et al, 2008). Thus, integrin β3 has become an 
interesting candidate for regulation of 5-HT systems. 
The focus of this thesis is the genetic and functional interaction between Itgb3 
and Slc6a4. The results provide evidence that a genetic interaction between Itgb3 and 
Slc6a4 modifies, SERT expression, transport activity, and anxiety- and depression-like 
behaviors. Pharmacological analysis revealed that synaptic SERT uptake can be 
modulated by integrin αvβ3 targeted compounds indicating a functional integrin αvβ3 x 
SERT interaction. These data highlight Itgb3 in brain 5-HT system regulation.  
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CHAPTER II 
 
IMMUNOHISTOCHEMICAL ASSESSMENT 
 
Localization of Integrin β3 in Serotonergic Neurons 
5-HT pathways have been well characterized in rodents as they have become a 
model system for studying pharmacotherapies and 5-HT dysregulation. In the brain, 5-
HT is synthesized in the raphe nucleus specifically, the dorsal raphe (DR) which 
contains approximately 50% of the brains serotonergic neurons (Jacobs and Azmitia, 
1992). Fibers originating from the dorsal raphe nuclei near ubiquitously innervates the 
brain including the cortex and hippocampus (Vertes, 1991). To determine if integrin β3 
was present in serotonergic neurons, immunohistochemistry experiments were 
performed utilizing wildtype (WT) and Itgb3-/- mice. Confocal imaging revealed integrin 
β3 expression in DR neurons (identified by NeuN) in WT (Figure 2B) but not Itgb3-/- 
mice (Figure 2A). Consistent with a recent finding using magnetic resonance imaging in 
mice (Ellegood et al, 2012) preliminary evidence was found for reduced neuron number 
in the DR of Itgb3-/- mice (Figure 2A). Sections probed for integrin β3 and the 5-HT 
synthesizing enzyme tryptophan hydroxylase 2 (TPH2) revealed robust colocalization in 
DR serotonergic neurons (Figure 2C). Integrin β3 x TPH2 colocalization was also found 
in the cortex and hippocampus (Figure 3) areas where the actions of 5-HT are known to 
mediate neuronal function and subsequent behavior (Akimova et al, 2009; Alexandre et 
al, 2006; Andrade, 2011; Schmidt et al, 2012). Last, confirmation of integrin β3 x SERT 
colocalization was found in DR neurons (Figure 4). These preliminary results indicate 
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integrin β3 localization in serotonergic neurons where it can affect 5-HT signaling. 
Furthermore, consistent with previous findings in platelets (Carneiro et al, 2008) the 
integrin β3 x SERT colocalization in the DR may be a direct protein-protein interaction, 
however this theory remains to be evidenced in the DR. 
 
Methods and Materials 
 
Immunohistochemistry 
Mice were perfused with 30 mL of 4% paraformaldehyde (Sigma). Following 
rapid decapitation mouse brains were removed and stored in 30% sucrose for 48 hrs at 
4o C. Brains were then sectioned on a frozen stage microtome (Leica) at 20 μM and 
stored in a cryoprotectant solution containing; 30 mL ethylene glycol, 30 mL H20, 10mL 
PBS, and 30 mL glycerol. Sections collected between ~4 mm and ~5 mm from bregma 
were defined as DR sections. Immunohistochemistry was performed using specific 
antibodies against integrin β3 (1:250, AbCam), SERT (1:2000, Frontier), TPH2 (1:250, 
Millipore), and NeuN (1:250, Millipore). Fluorescent secondary antibodies were applied 
at a 1:500 concentration. Images were captured using an LSM 510 Meta confocal. 
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Figure 2. Confocal image of integrin β3 (green) and NeuN (blue) immunohistochemical 
staining in the dorsal raphe nucleus of A) Itgb3-/- and B) Itgb3+/+ mice. C) 
Immunohistochemical probe for TPH2 (red) indicates integrin β3 localization in 
serotonergic neurons. 
 
Figure 4 A) Colocalization of integrin β3 (green), SERT (red) and NeuN (blue) 
immunohistochemical staining in the DR. B-C) Magnification of the region increases from left 
to right in the panel. 
 
Figure 3. A) Integrin β3 (green) and TPH2 (red) co-localization was 
also found the hippocampus (red box) and cortex (blue box). B) 
Increased magnification of the dentate gyrus. 
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CHAPTER II 
 
GENETIC ASSESSMENT: Itgb3-/+ x Slc6a4-/+ MOUSE MODEL 
 
Mouse Model 
To examine the influence of Itgb3 heterozygosity on SERT expression and 
uptake activity, 5-HT levels, and SERT-related behavioral phenotypes, mice 
heterozygous for Itgb3 (Itgb3-/+ ; I) and heterozygous for Itgb3 and Slc6a4 (Itgb3-/+ x 
Slc6a4-/+; IS) were generated. These mice were bred by crossing C57BL/6 males with a 
silencing mutation in the Itgb3 promoter region, Itgb3-/-, (Hodivala-Dilke et al; McHugh et 
al) with C57BL/6 females in which the Slc6a4 gene contains a silencing mutation in 
exon 14 which encodes the C-terminus, Slc6a4-/- (Zhao et al). Mice derived from this 
crossing were not used for experiments to avoid rearing effects caused by Slc6a4-/- dam 
phenotypes (Holmes et al; Kalueff et al, 2007a). Instead, the IS male offspring were 
paired with wildtype C57BL/6J females producing offspring of four genotypes: wildtype 
(WT), Itgb3-/+ (I), Slc6a4-/+ (S), Itgb3-/+ x Slc6a4-/+ (IS). Littermate males and females 
were utilized for all biochemical, neurochemical and behavioral assays. 
 
Analysis of SERT Expression and Function 
Slc6a4-/+ mice have been previously reported to express ~50% of SERT 
compared to WT (Bengel et al, 1998) and expression of Itgb3 and Slc6a4 are known to 
correlate (Weiss et al, 2006b). To determine effects of Itgb3 x Slc6a4 heterozygosity on 
midbrain 5-HT levels, SERT expression, and SERT transport function, were examined 
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in both tissue and synaptoneurosome preparations. Analysis of tissue levels of 5-HT 
and 5-hydroxyindoleacetic acid (5-HIAA) with were performed with high performance 
liquid chromatography (HPLC). No individual differences were found between 
genotypes, despite a Slc6a4 significant contribution to elevated midbrain 5-HT levels 
(WT: 11.2 + .46 ng/mg, n = 14; I: 10.63 + .36 ng/mg, n = 18; S: 12.03 + .34 ng/mg, n = 
18; IS: 11.49 + .55 ng/mg, n = 13; two-way ANOVA: Slc6a4 p < .05; Figure 5A). No 
significant differences were found in 5-HT turnover as measured by 5-HIAA/5-HT in the 
midbrain (WT: .75 + .06, n = 14; I: .79 + .04, n = 18; S: .68 + .04, n = 18; IS: .73 + .06 
ng/mg, n = 13; Figure 5B), however Slc6a4 significantly contributed to reduced turnover 
in the cortex (WT: .43 + .02, n = 14; I: .45 + .02, n = 18; S: .37 + .01, n = 18; IS: .39 + 
.02, n = 13; two-way ANOVA: Slc6a4 p < .05; Figure 5C), and hippocampus (WT: .61 + 
.06, n = 13; I: .67 + .05, n = 18; S: .54 + .04, n = 18; IS: .52 + .03 ng/mg, n = 12; two-
way ANOVA: Slc6a4 p < .05; Figure 5D). Western blot analysis of midbrain tissue 
revealed reduced expression of SERT in IS mice, (WT: 100 + 0%, n = 7; I: 98.42 + 
14.14%, n = 8; S: 51.9 + 9.33%, n = 7; IS: 34.81 + 7.98%, n = 6; Kruskal-Wallis one-way 
ANOVA: p < .005, Dunn’s post-hoc WT vs. IS p < .01, I vs. IS p < .05; Figure 5E). 
Next, synaptic SERT expression and function were analyzed in 
synaptoneurosome preparations which contain isolated pre- and post-synaptic 
components and attachments (Phillips et al, 2001). Again Western blot analysis 
revealed reduced SERT expression in midbrain samples (WT: 100 + 0%, n = 9; I: 89.88 
+ 19.4%, n = 12; S: 66.26 + 18.4%, n = 10; IS: 33.68 + 9.79%, n = 8; Kruskal-Wallis 
one-way ANOVA: p < .05, Dunn’s post-hoc WT vs. IS p < .05; Figure 6A), and a 
significant contribution of Slc6a4 to reduced [3H] citalopram binding in midbrain 
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synaptoneurosomes (WT: 143.8 + 14.46 fmols/min/mg, n = 12; I: 115.6 + 19.47 
fmols/min/mg, n = 12; S: 98.26 + 13.06 fmols/min/mg, n = 12; IS: 97.18 + 8.43 
fmols/min/mg, n = 12; two-way ANOVA: Slc6a4 p <.05; Figure 6B). To determine if 
reductions in SERT midbrain expression affected 5-HT uptake, synaptoneurosomes 
were exposed to increasing concentrations of [3H] 5-HT. Although I mice displayed 
significant reductions in midbrain Vmax compared to WT, IS mice exhibited normal 5-HT 
uptake (WT: 144.4 + 4.58 fmols/min/mg, n = 4; I: 91.19 + 3.33 fmols/min/mg, n = 4; S: 
142.1 + 5.3 fmols/min/mg, n = 4; IS: 156.7 + 8.45 fmols/min/mg, n = 4; one-way 
ANOVA: p < .0001; Bonferroni post-hoc WT vs. I p < .001, S vs. I p < .001. IS vs. I p < 
.0001; Figure 6B). No significant differences were detected in [3H] citalopram binding in 
synaptoneurosomes in the cortex (WT: 94.73 + 9.28 fmols/min/mg, n = 12; I: 75.13 + 
13.57 fmols/min/mg, n = 12; S: 107.4 + 12.47 fmols/min/mg, n = 12; IS: 91.69 + 15.74 
fmols/min/mg, n = 12; Figure 6C) although similar Vmax reductions were found in I mice 
compared to WT, S, and IS mice (WT: 84.37 + 5.79 fmols/min/mg, n = 4; I: 53 + 2 
fmols/min/mg, n = 4; S: 73.76 + 3.1 fmols/min/mg, n = 4; IS: 73.76 + 3.02 fmols/min/mg, 
n = 4; one-way ANOVA: p < .0001; Bonferroni post-hoc WT vs. I p < .001, S vs. I p < 
.05, IS vs. I p < .05; Figure 6C). In the hippocampus, again no significant differences 
were found in [3H] citalopram binding (WT: 222 + 25.54 fmols/min/mg, n = 12; I: 233.6 + 
20.7 fmols/min/mg, n = 12; S: 208.5 + 16.19 fmols/min/mg, n = 12; IS: 231.2 + 28.19 
fmols/min/mg, n = 12; Figure 6D), despite significant Vmax reductions in I mice compared 
to WT (WT: 160 + 12 fmols/min/mg, n = 4; I: 119.1 + 4.55 fmols/min/mg, n = 4; S: 150 + 
4.99 fmols/min/mg, n = 4; IS: 148.5 + 3.5 fmols/min/mg, n = 4; one-way ANOVA: p < 
.01; Bonferroni post-hoc WT vs. I p < .01; Figure 6D).  
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Figure 5. Slc6a4 contributes to brain 5-HT neurochemical measures. (A) HPLC analysis of 
midbrain tissue 5-HT revealed a significant contribution from Slc6a4 to elevated 5-HT levels (two-
way ANOVA main effect for Slc6a4: F(1,59) = 4.04, p < .05, n = 13-18) although no significant 
differences were found between genotypes (one-way ANOVA, p = .09). (B) Two- way ANOVA 
analysis also revealed Slc6a4 significant contributions to 5-HIAA/5-HT in (C) cortex (main effect 
for Slc6a4: F(1,58) = 6.28, p < .05, n = 13-18) and (D) hippocampus (main effect for Slc6a4: 
F(1,58) = 5.05, p < .05, n = 12-18) however Bonferroni post-hoc test could not detect individual 
genotype differences in either region. (E) Western blot analysis of midbrain tissue reveals 
significant reductions in IS mice compared to WT and I mice (Kruskal-Wallis one-way ANOVA, p 
< .005; Dunn’s post-hoc analysis revealed significant differences between IS mice and both WT 
(p < .01), and I (p < .05) mice n=6-7). All error bars = SEM, significance indicators as follows: * 
compared to WT, ^ compared to I.  
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Although IS mice displayed normal 5-HT uptake kinetics, I mice exhibited 
significant reductions in Vmax. The molecular alterations required for IS mice to exhibit 
normal 5-HT uptake may have be due to effects on the serotonergic system which may 
have gone undetected in the analysis. Previous reports of Slc6a4 double heterozygous 
or double knockout mouse models report only deficits due to the gene x gene 
interactions (Hagino et al, 2011; Page et al, 2009; Ren-Patterson et al, 2005), although 
gender differences in BDNF x SERT double knockout phenotypes have been reported 
(Ren-Patterson et al, 2006). The finding of rescued 5-HT uptake in IS mice may indicate 
a genetic compensation that is protective against Itgb3 heterozygosity and is engaged 
in the context of concurrent Itgb3 and Slc6a4 heterozygosity.  
In regards to brain 5-HT levels, HPLC tissue analysis of 5-HT levels may be 
insensitive to differences in extracellular and intracellular 5-HT. The zero-net flux 
method has been evidenced to be more sensitive than dialysate measurements and has 
routinely reported elevated extracellular 5-HT levels in mice with reduced SERT 
expression (Guiard et al, 2008; Mathews et al, 2004). It is likely that use of this method 
can find significant increases in extracellular 5-HT in S and IS mice compared to WT. 
 
Methods and Materials 
 
HPLC Assessment of Brain Amine Levels 
Mice were euthanized by rapid decapitation. The midbrain was dissected by 
making a coronal cut straight down through the brain just anterior to the superior 
colliculus (approximate bregma, −3.28). The cerebellum was removed and a second 
coronal cut was made just posterior to the inferior colliculus (approximate bregma,   
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Figure 6. Despite reduced SERT Expression, IS mice have normal 5-HT uptake (A) Western blot analysis 
of midbrain synaptoneurosomes reveals synapse specific reductions in SERT expression in IS mice 
compared to WT (Kruskal-Wallis one-way ANOVA, p < .05, n = 8-12; Dunn’s post-hoc analysis revealed 
significant differences between IS mice and WT, p < .05). (B) [3H] citalopram binding reveals Slc6a4 
dependent reductions in SERT expression in midbrain synaptoneurosomes (two-way ANOVA main effect 
for Slc6a4: F(1,44) = 4.92, p < .05, n = 12), however post-hoc analysis could not reveal individual genotype 
differences, saturation analysis revealed normal uptake in IS mice despite significant reductions uptake 
capacity in I mice (two-way ANOVA main effect for genotype: F(3,162) = 13.46, p < .0001, and 5-HT 
concentration F(5,162) = 41.45, p < .0001, n = 4), and Vmax measure shows I mice have significantly less 
uptake capacity than WT (p < .001), S (p < .001), and IS mice (p < .0001) due to a significant Itgb3 x 
Slc6a4 interaction (two-way ANOVA main effect for genotype: F(1, 8) = 8.73, p < .05, n = 4).Similar 
experiments were performed in on cortex and hippocampus synaptoneurosomes. (C) Analysis of cortical 
synaptoneurosomes revealed no significant differences in  [3H] citalopram binding (p = .38), however 
saturation analysis again revealed normal uptake in IS mice despite significant reductions uptake capacity 
in I mice (two-way ANOVA main effect for genotype: F(3, 119) = 5.79, p = .0001, and 5-HT concentration 
F(5,119) = 59.41, p < .0001, n = 4), and Vmax measure shows I mice have significantly less uptake capacity 
than WT (p < .005), S (p < .05), and IS mice (p < .05). (D) The hippocampus also displayed no significant 
differences in  [3H] citalopram binding (p = .24), however saturation analysis again revealed normal uptake 
in IS mice despite significant reductions uptake capacity in I mice (two-way ANOVA main effect for 
genotype: F(3, 168) = 3.66, p < .05, and 5-HT concentration F(5,168) = 75.52, p < .0001, n = 4), and Vmax 
measure shows I mice have significantly less uptake capacity than WT mice (p < .01). All error bars = SEM, 
significance indicators as follows: * compared to WT, # compared to S, and $ compared to IS. 
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−5.80). 5-HT, dopamine, and norepinephrine levels in tissue extracts were determined 
by HPLC by using an Antec Decade II electrochemical detector (oxidation, 0.5) 
operated at 33 °C in the Vanderbilt Center for Molecular Neuroscience Neurochemistry 
Core. Twenty microliter samples of the supernatant from trichloroacetic acid tissue 
extracts were injected via a Water 717+ autosampler onto a Phenomenex Nucleosil 
C18HPLC column (5u, 100A; 150 × 4.60 mm). Amines were eluted with a mobile phase 
consisting of 89.5% 0.1 M trichloroacetic acid, 10−2 M sodium acetate, 10−4 M EDTA, 
and 10.5% methanol (pH 3.8). Solvent was delivered at 0.6 ml/min by using a Waters 
515 HPLC pump. 
 
Synaptoneurosome Preparation 
Synaptoneurosomes were obtained as previously described (Veenstra-
VanderWeele et al, 2012). Briefly, mice were rapidly decapitated and brain regions were 
dissected and stored at 4 °C. Samples were homogenized in 10 mL of .32 M sucrose 
and centrifuged to isolate synaptoneurosomes.  
 
Western Blotting 
Midbrain synaptoneurosomes or trichloroacetic acid pellets retrieved from HPLC 
were resuspended in 1% sodium dodecyl sulfate in phosphate buffered saline pH 7.4 
and protein was measured by bicinchoninic acid kit (BCA Protein Assay Kit, Pierce 
Chemical Company, Rockford, IL). Concentrations of 20-50 μg of protein were loaded 
onto 17-well Pierce Protein Gels (Thermo Scientific). Gel electrophoresis was 
performed at 100 v for 3 hours then proteins were transferred overnight at 4 °C onto 
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PVDF membranes (Immoblin). After transfer membranes were blocked with 5% milk in 
1x tris-buffered saline pH 7.4 and incubated with antibodies at 1:250 or 1:1000 dilutions 
overnight at 4 °C. Secondary antibodies were added at 1:2500 dilution and proteins 
detected with chemiluminescence. Multiple exposures were taken to address linearity of 
the data. Films were scanned and proteins quantified by densitometry using Image J. 
Samples that showed significant background or degradation were excluded from 
analysis.  Antibodies included: mouse anti- GAPDH (Ambion), mouse anti-syntaxin 
(Millipore); and guinea pig anti-serotonin transporter (Frontier Science Co., LTD). 
 
[3H] Citalopram Binding 
Each tube contained 100 μg of midbrain synaptoneurosomes 50 μl binding 
buffer, 50 μl of 1 mM 5-HT or 250 μM fluoxetine, and 50 μl of 5 nM [3H] citalopram. 
Tubes were incubated on ice for 20 min then harvested via Brandel onto GF/B 
Whatman filters. Filters were dissolved overnight in scintillation fluid then radioactivity 
was quantified in a Packard counter by QuantaSmart 4.0 software. 
 
[3H] 5-HT Saturation Assays 
Each tube contained 100 μl of midbrain synaptoneurosomes (at 1 μg/μl) and 50 
μl assay buffer (containing 100 μM ascorbic acid and 100 μM paraglycine in KRH 
buffer). Parallel tubes were incubated with 10 μM citalopram to determine SERT specific 
uptake. Tubes were incubated for 10 min at 37 °C then 50 μl of vehicle, 500 nM, 1 mM, 
1.5 mM or 2 mM of [3H] 5-HT were added to duplicate tubes. Samples were incubated 
for 10 min at 37° C then harvested via Brandel onto GF/B Whatman filters. Filters were 
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dissolved overnight in scintillation fluid then radioactivity was quantified in a Packard 
counter by QuantaSmart 4.0 software. 
 
Autism-like Phenotype Analysis 
Itgb3 has been implicated in whole blood 5-HT levels (Weiss et al, 2004), and 
elevated whole blood 5-HT is a known biomarker of autism (Cook and Leventhal, 1996). 
HPLC analysis of whole blood 5-HT revealed no significant difference in IS mice 
compared to WT, however there was a Slc6a4 significant contribution to reduced blood 
5-HT (WT: 3597 + 246.7 ng/mg, n = 9; I: 3698 + 428.8 ng/mg, n = 8; S: 2675 + 354 
ng/mg, n = 7; IS: 3097 + 269.2 ng/mg, n = 9; two-way ANOVA: Slc6a4 p < .05; Figure 
7A). Repetitive and stereotypic behaviors are core symptoms of autism disorder and 
were examined in the marble burying and open field assays. No significant differences 
were found between genotypes in number of marbles buried (WT: 3.39 + 1, n = 13; I: 
2.6 + 1.02, n = 14; S: 4.14 + .84, n = 14; IS: 2.43 + 2.93, n = 14; one-way ANOVA: p = 
.57; Figure 7B). Although Slc6a4 significantly contributed to reduced stereotypic counts 
in the open field chamber, no genotype differences were found (WT: 5135 + 243.2, n = 
20; I: 4947 + 268.4, n = 24; S: 4437 + 258.8, n = 22; IS: 4404 + 276.4, n = 17; two-way 
ANOVA: Slc6a4 p < .05; Figure 7C). During a 10 min 3 chamber test of social behavior, 
Itgb3-/- mice displayed reduced interest in social interaction (Carter et al, 2011) another 
common symptom of autism disorder. WT and IS mice assayed in the same paradigm 
displayed a significant preference for the social stimulus (p < .001) while there were no 
significant differences between genotypes (WT: 200.83 s, + 22.36, n =12; IS: 184.77 s, 
+ 28.86, n =13; two-way ANOVA: stimulus p < .005; Figure 7D). In the novel interaction 
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condition, a significant preference was found for the novel mouse compared to the 
familiar mouse (p < .05), however no significant differences were found between 
genotypes (WT: 200.83 s, + 22.36, n =12; IS: 184.77 s, + 28.86, n =13; two-way 
ANOVA: stimulus p < .005; Figure 7E). No significant difference was found in entries 
into the left or right chamber (Figure 7F) indicating a side preference did not skew the 
data. The normal whole blood 5-HT levels, and stereotypic and social behavior, 
suggests that IS mice are not an autistic mouse model. 
 
 
Figure 7. IS mice exhibit normal whole blood 5-HT, stereotypic, and social behaviors (A) Whole blood 
5-HT in IS mice is normal compared to WT despite significant contribution from Slc6a4 to reduced 5-
HT (two-way ANOVA main effect for Slc6a4: F(1,27) = 6.38, p < .05, n = 7-9). (B) IS mice do not 
exhibit increases in marble burying behavior (one-way ANOVA, p = .57, n = 13-14). (C) IS mice do 
not exhibit increases in stereotypic behaviors during a 30 min OF (one-way ANOVA, p = .14, n = 18-
24). (D) IS mice show no deficit in social preference (two-way repeated measures ANOVA: main 
effect for stimulus F(1, 23) = 31.5, p < .0001 Bonferroni post-hoc analysis revealed a significant 
preference for the social stimulus in WT (p < .01,  n = 12) and IS (p < .005, n = 13) mice. (E) IS mice 
did not display significant differences in the amount of time spent with a novel mouse compared to a 
familiar mouse in (two-way repeated measures ANOVA: main effect for novelty F(1,23) = 6.4, p < 
.05).  Analysis of side preference revealed the random counterbalanced stimulus presentation was 
effective as mice did not exhibit preference for entering either side, unpaired t-test, t (.041, 98), p = 
.98, n = 13-14. All error bars = SEM.  
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Methods and Materials 
 
Open field  
After at least 1 hr acclimation under red light, mice were placed in light- and air 
controlled open field activity chambers (Med Associates, 27.9 x 27.9 x 20.5 cm) for 30 
min. Locomotor patterns were reported by 16 photocells in each horizontal direction. 
Data was extrapolated using the Activity Monitor software (Med Associates). The inner 
zone was defined as greater than 2 cm from the chamber wall.  
 
Marble burying 
Each mouse was placed in a novel cage with a 5 cm deep layer of bedding and 
allowed 30 min to acclimate. After 30 min the mice were removed from the cage. 20 
clean, transparent glass marbles (1.5 cm diameter) were placed on top of bedding in 
five rows of four marbles each, equally spaced apart. The mouse was then replaced in 
the cage for 20 min. After 20 min the mouse was removed from the cage and the 
number of marbles buried (at least 2/3 covered in bedding) was recorded. 
 
3-chamber social interaction test 
Social behavior was evaluated in a three chamber polycarbonate apparatus with 
4−inch sliding gates separating the 7 × 9−inch chambers. After at least 1 hr acclimation 
under red light, the subject mouse was initially allowed to explore all three chambers for 
10 min to acclimate to the apparatus. A stimulus mouse (social stimulus) was then 
introduced inside an inverted wire pencil cup (Spectrum Diversified Designs) in one side 
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of the chamber with a clean empty pencil cup (inanimate stimulus) introduced in the 
opposite side chamber. The stimulus mouse was an adult male WT mouse, previously 
habituated to the pencil cup. Videos were scored by trained observers blinded to 
genotype. 
 
Anxiety- and Depression-like Phenotype Analysis  
To determine contributions of Itgb3 heterozygosity to SERT-mediated anxiety- 
and depression-like phenotypes, further behavioral tests were analyzed. In a 30 minute 
open field test, Slc6a4 heterozygosity significantly contributed to reduced locomotor 
activity (WT: 3427 + 295.8 cm, n = 20; I: 3334 + 245.5 cm, n = 24; S: 2622 + 214.5 cm, 
n = 22; IS: 2744 + 317.2 cm, n = 17; two-way ANOVA: Slc6a4 p = .01; Figure 8A), 
however post-hoc analysis did not detect individual genotype differences. Further 
analysis revealed vertical exploratory behavior was significantly reduced in IS mice 
(WT: 156.1 + 19.16, n = 20; I: 135 + 19.48, n = 24; S: 126 + 25.38, n = 22; IS: 76 + 9.55, 
n = 17; Kruskal-Wallis one-way ANOVA: p < .05; Dunn’s post-hoc WT vs. IS p < .05; 
Figure 8B) specifically in the inner zone of the chamber (WT: 22.49 + 2.94, n = 20; I: 
15.99 + 2.36, n = 24; S: 22.8 + 3.9, n = 22; IS: 7.3 + 1.21, n = 17; Kruskal-Wallis one-
way ANOVA: p < .005; Dunn’s post-hoc WT vs. IS p < .01, S vs. IS p < .05; Figure 8C). 
Additionally, IS mice spent significantly less time in the inner zone than WT mice (WT: 
20.5 + 2.59%, n = 20; I: 18.11 + 2.4%, n = 24; S: 14.04 + 2.5%, n = 22; IS: 10.45 + 
1.82%, n = 17; one-way ANOVA: p < .05; Bonferroni post-hoc WT vs. IS p < .05; Figure 
8D). During a 5 min elevated zero maze assay no individual genotype differences were 
found however there was a significant contribution from Slc6a4 heterozygosity to  
reduced percent time in the open arm (WT: 47.41 + 2.43%, n = 20; I: 47.08 + 2.65%, n 
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= 21; S: 41.4 + 2.28%, n = 23; IS: 43.5 + 2.26%, n = 20; one-way ANOVA: p = .05; 
Figure 8F). Results from these exploratory and anxiety measures are consistent with 
previous reports of Slc6a4 heterozygosity effects on exploratory and anxiety-like 
behaviors (Holmes et al, 2003; Kalueff et al, 2007a; Kalueff et al, 2007b).  
As SERT deficiency is also implicated in depression-like behaviors (Ansorge et 
al, 2008; Lira et al, 2003; Zhao et al, 2006), behavioral tests of SERT related 
depression-like behaviors were performed (Bodnoff et al, 1988; Lucki et al, 2001). 
During a six minute forced swim test (FST), significant differences were found in 
immobility time during the first 2 min of the test (WT: 52.83 + 7.81 s, n = 14; I: 36.33 + 
4.53 s, n = 15; S: 46.57 + 10.4 s, n = 21; IS: 82.59 + 13.68 s, n = 16; Kruskal-Wallis 
one-way ANOVA: p < .05; Figure 8G), however post-hoc tests did not detect genotype 
differences. IS mice also exhibited significantly increased immobility during the last 4 
min of the FST (WT: 85.18 + 9.18 s, n = 27; I: 119.6 + 9.76 s, n = 27; S: 138 + 11.24 s, 
n = 21; IS: 143.3 + 11.35 s, n = 22; one-way ANOVA: p < .001; Bonferroni post-hoc WT 
vs. IS p < .005, WT vs. S p < .01; Figure 8H). As a further indicator to SERT regulation 
of these behaviors, correlation analysis revealed a significant correlation between SERT 
expression and immobility time in minute 4 of the FST (r = -.52, p < .005; Figure 8I).  
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Figure 8. IS mice exhibit a hypoexploratory, anxiety-, and depression-like phenotype. (A) 
Slc6a4 significantly contributes to a hypolocomotor phenotype in the open field test (two-way 
ANOVA main effect for Slc6a4: F(1, 79) = 6.8, p=.01, n =17-24. IS mice show reduced 
vertical exploration behavior in the open field apparatus (Kruskal-Wallis one-way ANOVA; p 
< .05, n = 17-24; Dunn’s post-hoc analysis reveals a significant reduction in IS mice 
compared to WT, p < .05) and, (C) in the center zone (Kruskal-Wallis one-way ANOVA, p 
<.05, n = 16-23; Dunn’s post-hoc analysis reveals a significant reduction in IS mice 
compared to WT mice, p < .05, I mice, p < .05, and S mice p < .05). (D) IS mice spend 
significantly less time in the center zone of the OF (two-way ANOVA main effect for Slc6a4: 
F(1, 79) = 8.4, p <.005, n = 17-24; Bonferroni post-hoc analysis reveals a significant 
difference in IS mice compared to WT, p < .05). (E) Although no significant differences were 
found in total distance traveled in the EZM (one-way ANOVA; p = .91, n = 20-23), (F) Scl6a4 
significantly contributed to time spent in the open arm of the maze (two-way ANOVA main 
effect for Slc6a4: F(1, 80) = 39.5, p =.05, n = 20-23). (G) A significant difference was 
detected in immobility time during the first two minutes of the FST (Kruskal-Wallis one-way 
ANOVA p < .05, n = 14-21), however post-hoc analysis did not reveal individual genotype 
differences. (H) During the last four min of the FST Slc6a4 heterozygosity contributed to 
greater immobility time (two-way ANOVA main effect for Slc6a4: F(1, 93)  = 13.65, p = .004; 
main effect for Itgb3: F(1, 93)  = 3.67, p = .058; WT, n = 27; I, n = 27; S, n = 22; IS, n = 16; 
Bonferroni post-hoc reveals a significant difference in both IS and S mice compared to WT 
(p < .005 and p < .01 respectively). (I) Correlation analysis revealed a significant correlation 
between tissue SERT expression and time immobile in minute 4 of the FST (Pearson r(25) = 
-.57, p < .005). All error bars = SEM. Significance indicators as follows: * compared to WT, # 
compared to I. 
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Methods and Materials 
 
Elevated Zero Maze 
The apparatus is 40 cm x 50 cm, and has four equidistance 5 cm wide arms. The 
two closed arms face opposite each other and have 15 cm walls. Each mouse was 
placed gently into the open arm of the maze and allowed to explore freely for 5 min. 
Mouse behavior was video-tracked and analyzed via ANY-maze software (Stoelting). 
 
Forced Swim Test 
The Porsolt forced swim test was used to measure depression-related behaviors 
(Cryan et al, 2005; Porsolt et al, 1977). Experimentation and analysis was conducted 
with the experimenter blinded to animal genotypes. The testing apparatus consisted of a 
clear Plexiglas cylinder with water approximately 20 cm deep and 23 C. After at least 1 
hr acclimation under red light, mice were tested for 6 min. After 6 min, the number of 
fecal boli produced during the test was counted and the animals were removed and 
placed in clean, heated cages for 15 min to recover. All tests were recorded by video 
camera and scored by an observer blinded to the genotypes. Following each test, the 
testing cylinders were drained, cleaned, and refilled with clean water. Immobility was 
defined as minimal movement necessary for the animal to keep its head above water. 
Immobile behavior was recorded in one-minute bins. The primary dependent variable 
was immobility time in the last 4 min of the test, which has been shown to be sensitive 
to anti-depressant effects. Additional dependent variables included latency to first 
immobile period and immobility time in the first 2 min.  
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CHAPTER IV 
 
PHARMACOLOGICAL ASSESSMENT: INTEGRIN αvβ3 X SERT FUNCTIONAL 
INTERACTION 
 
Integrin αvβ3 Regulation of SERT Uptake Activity 
Integrin antagonists have traditionally utilized the high affinity Arginine-Glycine-
Aspartic acid (RGD) binding domain (Hynes, 1992), and integrin effects on synaptic 
functions in response to cyclo-RGD (cRGD) peptide mimetics have been reported 
(Watson et al, 2007). RGD ligands are known to regulate the integrin II3 x SERT 
interaction in platelets (Carneiro et al, 2008). Based on these findings, integrin v3 
targeted cRGD analogs IDT 494 and IDT 500 were synthesized to explore integrin v3 
x SERT functional interactions. Carneiro, et al., demonstrated that activation of platelet 
integrin II3 significantly increases SERT [3H] 5-HT uptake (Carneiro et al, 2008). 
Similarly, in WT midbrain synaptoneurosomes [3H] 5-HT uptake assays revealed effects 
on SERT uptake activity in response to integrin v3 targeted compounds. Specifically, 
at concentrations of 1-100 nm IDT 494 increased SERT uptake (p < .05, n = 4; Figure 
9B), while .1 nM IDT 500 decreased SERT uptake (p < .05, n = 3; Figure 9C), indicating 
that integrin v3 can differentially modulate synaptic SERTs. Also assayed were other 
compounds which contain RGD sites or otherwise bind to integrin v3. 10 nM RGD 
significantly increased SERT uptake (p < .05, n = 4; Figure 9A). Resveratrol is a natural 
polyphenol found in grapes and other fruits. It has come under investigation as an anti-
cancer agent and has been found to act through its RGD sequence binding integrin 
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v3 (Hsieh et al, 2011; Lin et al, 2006). At concentrations of 50-100 μm resveratrol 
significantly reduced SERT uptake (p < .005, n = 3; Figure 9D). Echistatin is a naturally 
occurring disintegrin which also contains the high affinity RGD sequence (Kumar et al, 
1997). Echistatin had no effect on SERT uptake at comparable concentrations (p = .71, 
n = 3; Figure 9E). Lastly, MnCl2, which is known to bind to metal ion-dependent 
adhesion sites as opposed to the RGD binding-site (Hynes, 2002a), also had no effect 
on SERT uptake (p = .75, n = 4; Figure 9F). 
  
 
Figure 9. Pharmacological targeting of the integrin v3 RGD binding site regulates SERT 
uptake activity. A) 10 nM cRGD significantly increased uptake (p < .01). B) IDT 494 
significantly increased uptake at concentrations of 1-100 nM (p < .05). C) IDT 500 decreased 
uptake at .1 nM (p < .05). D) Resveratrol reduced uptake at concentrations of 50-100 μM (p < 
.05), p < .01, respectively). (E) Echistatin had no effect of SERT uptake at comparable 
concentrations. (F) MnCl2 which binds to an alternate site in integrin v3 also had no effect 
on uptake activity. Repeated measures ANOVA with Dunnett’s post-hoc analysis, n = 3-6 for 
each experiment. All error bars = SEM. 
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As IDT 500 and resveratrol both exhibited SSRI-like effects on SERT uptake, 
they were further probed to determine if they were specific for integrin v3. Since 
integrin 3 only forms dimers with integrin v and IIb (Hynes, 2002a), and integrin IIb 
is not expressed in brain (Wu and Reddy, 2012), Itgb3-/- mice experiments allowed for 
determination of specificity for integrin v3 as opposed to the multitude of integrin - 
and - subunit combinations that form RGD receptors and are expressed in the brain 
(Wu et al, 2012). [3H] 5-HT uptake assays in Itgb3-/- mice proved specificity of IDT 500 
for integrin v3 uptake (p < .005, n = 5; Figure 10a), since the compound had no effect 
on [3H] 5-HT uptake in Itgb3-/- midbrain synaptoneurosomes (p = .94). Resveratrol 
proved to be non-specific for integrin v3 as it significantly reduced uptake in both WT 
and Itgb3-/- synaptoneurosomes (p < .005, n = 5; and p < .05, n = 4; respectively; Figure 
10B). 
        A                                                                                B       
 
 
Figure 10. A) IDT 500 reduces uptake in WT [t (4.96, 8), p < .005, n = 5], and has no effect on 
uptake in Itgb3-/- [t (.07, 8), p = .95, n = 5] midbrain synaptoneurosomes. B) Resveratrol 
significantly reduces 5-HT uptake in both WT [t (4.37, 6), p < .005, n = 4] and Itgb3-/- [t (2.64, 6), 
p < .05, n = 4] midbrain synaptoneurosomes. Two-tailed unpaired t-tests. All error bars = SEM. 
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 Results from these experiments suggests that RGD targeting of integrin v3 can 
regulate midbrain SERT uptake activity leading to the working model in Figure 11. 
 
  
 
Figure 11. Working model of IDT 494 and IDT 500 regulation of SERT activity via integrin 
v3. IDT 494 may regulate SERT uptake activity via increasing SERT expression at the 
plasma membrane, or increasing SERT catalytic activity, while IDT 500 may regulate SERT 
uptake by decreasing SERT expression or decreasing SERT catalytic activity.  
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Methods and Materials 
 
[3H] 5-HT uptake assays 
Midbrain synaptoneurosomes were obtained and normalized to a concentration 
of 1 μg/ μl. 100 μl of synaptoneurosomes were then incubated for 10 min at 37o C in test 
tubes containing 100 μl of assay buffer, and 50 μl of drug. Next, samples were 
incubated with [3H] 5-HT for 10 min at 37o C.  An identical set of tubes contained 50 μl of 
10 nM citalopram to define SERT specific uptake. Next samples were harvested via 
Brandel onto GF/B Whatman filters. Filters were dissolved overnight in scintillation fluid 
then radioactivity was quantified in a Packard counter by QuantaSmart 4.0 software. 
Echistatin, resveratrol, and cRGD were purchased from Tocris Biosciences. IDT 494 
and IDT 500 were synthesized at Vanderbilt University by Ian Tomlinson, Ph.D. 
 
 
Analysis of Kinase Activity 
Since integrins are enzymatically inactive, they must rely on adaptor molecules to 
confer signaling and regulate cell functions. Integrin II3 signaling through p38 MAPK 
is a known regulator of SERT plasma membrane expression and catalytic activity in 
platelets (Carneiro et al, 2008). Recently, the tyrosine kinase Src was found to regulate 
synaptosome plasma membrane expression and uptake activity of SERT via 
phosphorylation of Tyr47 and Tyr 142 (Annamalai et al, 2012). Src is known to directly 
associate with the c-terminus of integrin 3 (Arias-Salgado et al, 2003), and activation of 
integrin v3 by RGD peptides leads to Src phosphorylation and activation (Alghisi et 
al, 2009).  
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To determine if kinase signaling mediated the integrin v3 x SERT uptake 
effect, midbrain synaptoneurosomes were incubated in vehicle, 10 nM cRGD, 10 nM 
IDT 494, 100 μM resveratrol, or 1 mM MnCl2. Synaptoneurosomes were then probed for 
kinase activity via Western blot. No significant differences were found for any of the 
tested RGD compounds in Src activity, however 1 mM MnCl2 significantly reduced Src 
activity (p < .05, n = 7; Figure 11A). None of the tested compounds significantly affected 
ERK activity (p = .3, n = 7; Figure 11B).  
 
Figure 12. Western blot analysis of midbrain synaptoneurosomes did not reveal changes in 
kinase activity in response to RGD compounds. However, Src activity was significantly 
reduced by MnCl2 (Repeated measures one-way ANOVA, Dunnett’s post-hoc analysis, p < 
.05, n = 7). (B) ERK activity was not significantly altered by any of the compounds (Repeated 
measures one-way ANOVA, p = .30, n = 7). All error bars = SEM. 
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It is possible that kinase signaling is not responsible for integrin v3 mediated 
changes in SERT activity. The cytoplasmic tail of integrin 3 is known to regulate 
expression and function of GluA2 AMPA (Pozo et al, 2012) and VEGF type 2 (West et 
al, 2012) receptors via direct interactions with their cytoplasmic tails. Binding of integrin 
v3 specific compounds could result in conformation changes in the integrin 3 
cytoplasmic tail which can then directly regulate SERT.  
 
Methods and Materials 
 
Microcentrifuge tubes contained 50 μl of vehicle/drug and to 450 μl of midbrain 
synaptoneurosomes (at 1 μg/μl). Samples were incubated for 20 minutes at 37o C. 
Samples were re-pelleted by centrifugation. The supernatant was removed and the 
pellet was resuspended in 100µl of 1x-Tris (pH-7.4), 1% SDS, and 25µl lammeli buffer 
(containing β-mercaptoethanol). Western blotting was performed as previously 
described in chapter III. Primary antibodies included: Total and phosphorylated Src (Cell 
Signaling, 1:1000), and total and phosphorylated ERK (Cell Signaling, 1:1000). Protein 
expression was quantified as described in chapter III.  
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CHAPTER V 
 
SYNOPSIS AND CONCLUSION 
 
 Immunohistochemistry experiments provided preliminary evidence for integrin β3 
localization in serotonergic neurons (Figure 2C & 3), in close proximity to SERT (Figure 
4). Additionally, it appeared that knockout of Itgb3 led to a reduction in the number of 
neurons in the DR, consistent with recent imaging results (Ellegood et al, 2012). The 
presence of integrin β3 in DR serotonergic neurons, previous evidence of a functional 
integrin αIIbβ3 x SERT interaction in platelet function (Carneiro et al, 2008), a genetic 
interaction in human and mouse brain (Weiss et al, 2006b), and an Itgb3 x Slc6a4 
contribution to increased autism risk (Ma et al, 2010; Napolioni et al, 2011; Weiss et al, 
2006a) provided the evidence needed to further investigate the integrin αvβ3 x SERT 
interaction in brain. 
Despite previous reports implicating ITGB3 in whole blood 5-HT levels (Weiss et 
al, 2005; Weiss et al, 2004) and autism risk (Ma et al, 2010; Napolioni et al, 2011; 
Weiss et al, 2006a), and Itgb3-/- mice exhibiting reduced social preference (Carter et al, 
2011), experiments reported here did not reveal Itgb3 heterozygosity influences on 
whole blood (Figure 7A) or midbrain tissue 5-HT levels (Figure 5A). Neither did Itgb3 
heterozygosity influence stereotypic and repetitive, or social behavior (Figure 7B-D). In 
humans, the gain-of function Leu33Pro ITGB3 polymorphism is associated with whole 
blood levels (Weiss et al, 2004), while the Leu33 allele is associated with autism risk 
(Weiss et al, 2006a). Additionally, there is confusion regarding involvement of SLC6A4 
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polymorphisms in autism risk. Polymorphisms in the extensively studied SLC6A4 
promoter region (5-HTTLPR) have implicated increased risk for autism for both the s 
allele (Cook et al, 1997), associated with reduced transporter expression and function 
(Lesch et al, 1996), and the nominal l allele (Klauck et al, 1997). There is also evidence 
that each 5-HTTLPR polymorphism is linked to a particular symptomology of the 
disorder (Brune et al, 2006). Recently, the gain-of-function Gly56Ala polymorphism has 
been shown to cause hyperserotonemia, social impairments, and increased repetitive 
behavior in a transgenic mouse model (Veenstra-VanderWeele et al, 2012), while Pten-
/+ x Slc6a4-/+ mice exhibit reductions in social behavior (Page et al, 2009). These mixed 
result suggest that it is likely that no autism-like phenotypes were detected in the IS 
mouse model because different combinations of genetic and molecular interactions 
result in different phenotypes.  
 Additional results from the IS mouse model experiments indicate that while Itgb3 
heterozygosity can significantly reduce 5-HT uptake (Figure 6B-D), and exaggerate 
biochemical and behavioral phenotypes such as reduced Slc6a4 expression (Figure 5E 
and Figure 6A), reduced exploratory behavior (Figure 8B-C), increased anxiety-like 
behavior (Figure 8D), and increased depression-like behavior (Figure 8G-H), the 
phenotypes are largely driven by Slc6a4 heterozygosity. Taken together with IS mice 
being the sole genotype to have significant reductions in midbrain tissue and midbrain 
synaptoneurosome SERT expression, it is likely that dose-dependent reductions in 
SERT expression underlie these behavioral phenotypes, with IS mice demonstrating 
phenotype characteristics between S and Slc6a4-/- mice (Holmes et al, 2002; Kalueff et 
al, 2007b; Lira et al, 2003). Thus it would appear that integrin β3 acts on the 
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serotonergic system either directly through SERT or in a similar fashion as SERT to 
modulate brain function and subsequent behavioral phenotypes.  
 The pharmacological assessment provided preliminary insight into how integrin 
αvβ3 can modulate the serotonergic system since targeting of integrin αvβ3 could 
increase or decrease SERT-mediated 5-HT uptake (Figure 9A-D). That integrin αvβ3 
targeting compounds differentially regulate SERT uptake suggests that in vivo 5-HT 
actions can be enhanced or limited via endogenous integrin αvβ3 ligands. Furthermore, 
these experiments provide evidence for integrin αvβ3 as a potential therapeutic target 
for serotonergic systems in human brain, and highlight 5-HT phenotypes such as 
anxiety and depression, as possible side effects for persons prescribed integrin αvβ3 
targeted therapeutics. The exact mechanism underlying the integrin αvβ3 X SERT 
interaction remained elusive as experiments into the prime candidate (kinase signaling) 
did not yield results (Figure 12). However, it is possible that Western blot is not a 
sensitive enough technique to detect kinase activity alterations in as complex a system 
as the brain, where multitudes of kinase signaling pathways are regulating numerous 
synaptic functions.  
These findings highlight integrin β3 as a modulator of brain serotonergic systems. 
It remains to be elucidated if this occurs through a direct interaction or integrin β3 kinase 
signaling. The results suggest that persons possessing polymorphisms which result in 
an Itgb3-/+ x Slc6a4-/+ genotype and persons prescribed integrin αvβ3 compounds may 
be at increased risk for developing 5-HT related disorders, such as anxiety. Further 
experimentation is required to confirm these findings, determine the mechanism of 
action, and provide insight into in vivo relevance of the integrin αvβ3 x SERT interaction.  
C 
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